Source comparison
Melanotan-2 Administration Route Comparison
Subcutaneous injection 80–95% None (bypasses oral cavity) Minimal (proteases inactive in subcutaneous tissue) High (measured doses in mg, 0.1mg precision) >90% (primary barrier is needle aversion, not protocol difficulty) Sublingual (under tongue) 5–15% Severe
This comparison does not assign a generated winner or score.
- Subcutaneous injection
- 80–95%
- None (bypasses oral cavity)
- Minimal (proteases inactive in subcutaneous tissue)
- High (measured doses in mg, 0.1mg precision)
- >90% (primary barrier is needle aversion, not protocol difficulty)
- Sublingual (under tongue)
- 5–15%
- Severe (sustained contact with taste receptors for 60–90 seconds)
- High (salivary enzymes degrade 30–50% before absorption)
- Moderate (solution volumes measured in mL, dilution errors common)
- <30% (taste and inconsistent absorption drive discontinuation)
- Oral (swallowed)
- 1–5%
- Moderate to severe (brief tongue contact, gastric reflux extends exposure)
- Extreme (gastric acid and intestinal proteases degrade >90% of dose)
- Low (dose must be 10–20× higher, increasing cost and side effect risk)
- <10% (inefficacy and cost drive discontinuation)
- Subcutaneous injection is the only administration route that consistently delivers predictable plasma concentrations of intact Melanotan-2. Oral and sublingual routes require dose escalation to compensate for poor bioavailability, but higher doses do not proportionally increase absorption—they increase the fraction of peptide degraded in the GI tract and the intensity of the bitter taste. The comparison is not close: injection is the clear standard for any research protocol requiring reproducible melanocortin receptor activation.